EA201890355A1 - Новые способы индукции иммунного ответа - Google Patents

Новые способы индукции иммунного ответа

Info

Publication number
EA201890355A1
EA201890355A1 EA201890355A EA201890355A EA201890355A1 EA 201890355 A1 EA201890355 A1 EA 201890355A1 EA 201890355 A EA201890355 A EA 201890355A EA 201890355 A EA201890355 A EA 201890355A EA 201890355 A1 EA201890355 A1 EA 201890355A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immune response
new methods
related antigen
response induction
methods
Prior art date
Application number
EA201890355A
Other languages
English (en)
Russian (ru)
Inventor
Мари-Анж Демуатье
Мари-Ноэль Доннер
Надиа Уакед
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201890355A1 publication Critical patent/EA201890355A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201890355A 2015-07-27 2016-07-25 Новые способы индукции иммунного ответа EA201890355A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1513176.6A GB201513176D0 (en) 2015-07-27 2015-07-27 Novel methods for inducing an immune response
PCT/EP2016/067622 WO2017017050A1 (en) 2015-07-27 2016-07-25 Novel methods for inducing an immune response

Publications (1)

Publication Number Publication Date
EA201890355A1 true EA201890355A1 (ru) 2018-08-31

Family

ID=54106649

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890355A EA201890355A1 (ru) 2015-07-27 2016-07-25 Новые способы индукции иммунного ответа

Country Status (15)

Country Link
US (4) US20180216081A1 (cg-RX-API-DMAC7.html)
EP (2) EP3328420A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018521666A (cg-RX-API-DMAC7.html)
KR (1) KR20180034589A (cg-RX-API-DMAC7.html)
CN (2) CN108135991A (cg-RX-API-DMAC7.html)
AR (1) AR105470A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016301029B2 (cg-RX-API-DMAC7.html)
BE (2) BE1023916A9 (cg-RX-API-DMAC7.html)
BR (2) BR112018001572A2 (cg-RX-API-DMAC7.html)
CA (2) CA2993371A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890355A1 (cg-RX-API-DMAC7.html)
GB (1) GB201513176D0 (cg-RX-API-DMAC7.html)
IL (1) IL257071A (cg-RX-API-DMAC7.html)
MX (2) MX2018001215A (cg-RX-API-DMAC7.html)
WO (2) WO2017017049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
DK3436591T5 (da) * 2016-03-31 2024-09-16 The European Molecular Biology Laboratory Adenovirale coat-protein-afledte transportvehikler
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3697919A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals SA Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
CN111479926A (zh) * 2017-10-16 2020-07-31 葛兰素史密丝克莱恩生物有限公司 具有两个表达盒的猿猴腺病毒载体
CN111655847A (zh) * 2017-10-16 2020-09-11 葛兰素史密丝克莱恩生物有限公司 能够复制的腺病毒载体
BR112020007042A2 (pt) * 2017-10-16 2020-11-17 Glaxosmithkline Biologicals S.A. promotor intensificado
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
WO2019239311A1 (en) * 2018-06-12 2019-12-19 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2020033876A1 (en) 2018-08-10 2020-02-13 Nantbio, Inc. Cellular adjuvants for viral infection
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN110283766B (zh) * 2019-05-13 2020-12-18 华中科技大学 一种重组卡介苗及其构建与应用
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗
WO2021067448A1 (en) * 2019-09-30 2021-04-08 Applied Genetic Technologies Corporation Adeno-associated virus (aav) systems for treatment of genetic hearing loss
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
CN113088538A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN114438128A (zh) * 2020-10-30 2022-05-06 上海市公共卫生临床中心 一种增强型溶瘤腺病毒及其应用
US20240033334A1 (en) * 2020-12-04 2024-02-01 Gritstone Bio, Inc. Compositions and methods of use thereof
JP2024534178A (ja) * 2021-08-31 2024-09-18 ヴィア・バイオテクノロジー・インコーポレイテッド 結核ワクチン
CN118662620A (zh) * 2023-03-15 2024-09-20 康希诺生物股份公司 一种肺结核疫苗及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ319377A (en) 1995-09-01 2000-01-28 Corixa Corp polypeptides comprising a portion of a soluble M tuberculosis antigen
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
AU2001268678B2 (en) * 2000-06-20 2006-11-16 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2993042A1 (en) * 2004-01-23 2005-08-04 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
ES2442225T3 (es) 2004-04-28 2014-02-10 The Trustees Of The University Of Pennsylvania Régimen de inmunización con cebado de adenovirus suprimido en E4 y potenciación de adenovirus suprimido en E1
JP5164830B2 (ja) * 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
AU2006257323B2 (en) 2005-06-17 2011-12-22 Msd Italia S.R.L. Hepatitis C virus nucleic acid vaccine
HRP20161606T1 (hr) 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
WO2009105084A2 (en) * 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP3385387B1 (en) * 2009-02-02 2021-08-25 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
US8932600B2 (en) * 2010-01-27 2015-01-13 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
TR201902214T4 (tr) * 2010-04-16 2019-03-21 Glaxosmithkline Biologicals Sa Şempanze adenoviral vektörü-bazlı filovirüs aşıları.
PT3023106T (pt) * 2010-12-14 2019-11-04 Glaxosmithkline Biologicals Sa Composição antigénica de micobactéria
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
BE1024420B1 (fr) 2015-06-12 2018-02-19 Glaxosmithkline Biologicals Sa Polynucleotides et polypeptides d'adenovirus

Also Published As

Publication number Publication date
KR20180034589A (ko) 2018-04-04
WO2017017050A1 (en) 2017-02-02
AR105470A1 (es) 2017-10-04
US20210060150A1 (en) 2021-03-04
AU2016301029B2 (en) 2019-08-22
CA2993371A1 (en) 2017-02-02
MX2018001215A (es) 2018-04-13
JP2018524393A (ja) 2018-08-30
MX2018001213A (es) 2018-04-13
US20180250375A1 (en) 2018-09-06
CN108135991A (zh) 2018-06-08
BR112018001683A2 (pt) 2018-09-18
BE1023915B1 (fr) 2018-01-31
AU2016301029A1 (en) 2018-02-01
GB201513176D0 (en) 2015-09-09
US20180216081A1 (en) 2018-08-02
BR112018001572A2 (pt) 2018-11-06
BE1023916A9 (fr) 2018-02-12
BE1023916B1 (fr) 2018-01-22
BE1023916A1 (fr) 2017-09-12
IL257071A (en) 2018-03-29
WO2017017049A1 (en) 2017-02-02
EP3328420A1 (en) 2018-06-06
CN108367061A (zh) 2018-08-03
BE1023915A9 (fr) 2018-01-24
CA2993277A1 (en) 2017-02-02
BE1023915A1 (fr) 2017-09-12
US20210386846A1 (en) 2021-12-16
EP3328421A1 (en) 2018-06-06
JP2018521666A (ja) 2018-08-09
US11110159B2 (en) 2021-09-07

Similar Documents

Publication Publication Date Title
EA201890355A1 (ru) Новые способы индукции иммунного ответа
CY1125241T1 (el) Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους
EA202091004A1 (ru) Аденовирус и пути его применения
EA202091074A1 (ru) Аденовирус и его применения
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
MX2017014532A (es) Vacunas para el tratamiento y prevencion del cancer.
TR201908550T4 (tr) Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
PH12019500596A1 (en) Recombinant binding proteins and their use
EA201891460A1 (ru) Композиция дендритных клеток
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201790239A1 (ru) Молекула-носитель для антигенов
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
EA201591798A1 (ru) Композиции и способы усиления иммунного ответа на кишечные патогены
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201800148A1 (ru) Оспенная вакцина для лечения рака
MY188100A (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
EA202091104A1 (ru) Аденовирус и пути его применения
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
EA201891287A1 (ru) Вакцинация с использованием альфа 3-домена mica/b для лечения рака